Autolus Therapeutics (AUTL) Cash from Financing Activities (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Cash from Financing Activities data on file, last reported at -$1.8 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 105.99% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.3 million (down 100.74% YoY) and the FY2025 annual result came in at -$4.3 million, down 100.74% from the prior year.
• Cash from Financing Activities fell to -$1.8 million in Q4 2025, from -$1.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $561.4 million in Q1 2024 to a low of -$2.1 million in Q2 2024.
• A 5-year average of $60.7 million and a median of $13500.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 69000.0% — and 2024, when it jumped 130365.22%.
• Tracing AUTL's Cash from Financing Activities over 5 years: stood at $147.4 million in 2021, then jumped by 51.62% to $223.5 million in 2022, then plunged by 99.99% to $23000.0 in 2023, then jumped by 130365.22% to $30.0 million in 2024, then plunged by 105.99% to -$1.8 million in 2025.
• The last three Cash from Financing Activities figures came in at -$1.8 million (Q4 2025), -$1.8 million (Q3 2025), and -$768000.0 (Q2 2025), per Business Quant data.